SLC6A3 and Parkinson disease: On the one hand, LILRB4 appears to exert beneficial effects on the nigrostriatal dopamine system, including reduced α‐synuclein deposition, improved DAT function, and enhanced DA and its metabolite, which could delay the onset of motor dysfunction in PD.